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Abstract
Introduction—Renal dysfunction is among the most common complication of sickle cell disease 
(SCD), from hyposthenuria in children to progression to overt chronic kidney disease (CKD) in 
young adults. Emerging evidence now suggests that sickle hemoglobin-related nephropathy 
extends to individuals with sickle cell trait (SCT).
Areas covered—This review will highlight the pathophysiology, epidemiology, and 
management recommendations for sickle hemoglobin-related nephropathy in both SCD and SCT. 
In addition, it will focus on the major demographic and genetic modifiers of renal disease in 
sickling hemoglobinopathies.
Expert commentary—Studies have elucidated the course of renal disease in SCD; however, the 
scope and age of onset of renal dysfunction in SCT has yet to be determined. In SCD, several 
modifiers of renal disease – such as α-thalassemia, hemoglobin F, APOL1 and HMOX1 – have 
been described and provide an opportunity for a precision medicine approach to risk stratify 
patients who may benefit from early intervention. Extrapolating from this literature may also 
provide insight into the modifiers of renal disease in SCT. Further studies are needed to determine 
the optimal treatment for sickle hemoglobin-related nephropathy.
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1. Introduction
Renal manifestations are among the most common complications of sickle cell disease 
(SCD), from the near universal finding of hyposthenuria in children to progression to end-
stage renal disease (ESRD) in adults—a continuum referred to as sickle nephropathy. The 
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hypoxic, acidotic, and dehydrated environment of the renal medulla promotes erythrocyte 
sickling, ultimately leading to ischemic-reperfusion injury, vasculopathy, and glomerular 
damage. However, while the relationship between renal impairment and SCD—a term used 
to describe several genotypes including hemoglobin SS/Sβ°, SC and Sβ+ thalassemia—has 
long been recognized, the association between chronic kidney disease (CKD) and 
hemoglobin AS or sickle cell trait (SCT) has only recently been established. This review will 
highlight the pathophysiology, epidemiology, and management recommendations for sickle 
hemoglobin-related nephropathy in both SCD and SCT. In addition, we will discuss 
demographic and major genetic modifiers of renal disease in sickling hemoglobinopathies 
and the role of precision medicine in identifying individuals who may benefit from early 
intervention.
2. Pathophysiology of sickle cell nephropathy
The unique physiologic environment of the kidney leads to susceptibility to renal injury in 
SCD. The renal medulla has particularly low oxygen tension, hyperosmolarity, and low pH, 
all of which promote hemoglobin S (HbS) polymerization and subsequent sickling of red 
blood cells in SCD. The typical understanding of SCD-related kidney disease suggests that 
repetitive episodes of sickling lead to ischemic injury and microinfarction, ultimately 
resulting in loss of the vascular architecture of the renal medulla [1]. This vaso-occlusion 
and microinfarction is thought to contribute to several of the noted clinical features of SCD-
related kidney disease, including altered urinary concentration, hematuria, and indirectly, 
hyperfiltration [2,3]. As noted in murine models of ischemic renal injury, transgenic sickle 
mice demonstrate substantially greater renal injury than wild-type mice and even 
demonstrate injury in the kidney contralateral to the induced ischemic insult [4].
Glomerular hyperfiltration and renal hyperperfusion are also common features in SCD, 
occurring as early as infancy [2,5]. While the mechanisms of hyperfiltration are not 
completely understood, it is thought to be indirectly triggered by medullary hyperperfusion 
as described above. In response to medullary ischemia, vasodilatory substances, including 
prosta-glandins, are released leading to reduced renal vascular resistance and increased 
effective renal arterial blood flow [6]. Further studies have suggested additional mechanisms 
may also contribute to hyperfiltration. For example, transgenic sickle cell mice exhibit 
increased expression of heme oxygenase-1 (HO-1) in the kidney and other tissue beds as 
part of a response to oxidative stress. HO-1, in turn, leads to increased production of carbon 
monoxide (CO) which is also local vasodilatory properties [5,7].
Endothelial dysfunction has been described in SCD and also likely plays an important role 
in the pathogenesis of sickle cell kidney disease. Soluble fms-like tyrosine kinase 1 
(sFLT-1), a splice variant of vascular endothelial growth factor receptor 1 (VEGFR1) binds 
circulating VEGF, prevents its interaction with endothelial cells, and ultimately induces 
endothelial dysfunction. A study of 73 SCD patients demonstrated an association between 
sFLT-1 and worsening albuminuria suggesting a contribution to sickle cell nephropathy [8]. 
Endothelin-1 (ET-1), a peptide with potent vasoconstrictive properties, is produced by 
endothelial cells in response to various insults, including sheer stress, hypoxia, and 
inflammatory signals. ET-1 mediates endothelial dysfunction by reducing NO bioavailability 
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and induces direct injury to podocytes via the ETA receptor [9,10]. In sickle cell mouse 
models, ET-1 has been demonstrated to mediate glomerular injury via reactive oxygen 
species, and ETA receptor antagonism appears to afford renal protection [11,12]. In patients 
with SCD, ET-1 has also been demonstrated to be associated with albuminuria and measures 
of vascular dysfunction [13].
Finally, hemolysis itself may contribute to the development of kidney disease due to the 
increase in levels of plasma free hemoglobin and subsequent hemoglobinuria. Free heme 
filtered through the glomerulus is directly cytotoxic to renal tubular epithelial cells, which 
subsequently induces damaging inflammatory responses [10]. A recent study also found that 
hemoglobin competes with filtered albumin by binding to megalin and cubilin in the 
proximal tubule. Albumin resorption is impaired leading to tubular proteinuria (independent 
of glomerular damage) that likely also induces renal injury [14]. Kidney biopsy specimens 
of individuals with SCD may demonstrate hemosiderin deposition in glomerular and tubular 
epithelial cells [15]. Clinical studies have demonstrated an association between hemolysis 
markers and albuminuria [16,17]. Additionally, data from a combined cohort study 
confirmed a relationship between hemoglobinuria and progressive CKD [18].
Progressive of kidney damage in SCD is likely driven by a multitude of processes including 
those described above. Hyperfiltration and its associated hemodynamic changes injure the 
glomerular endothelium, filtration barrier, and parietal epithelium. These injuries are thought 
to produce the characteristic lesion of focal segmental glomerulosclerosis (FSGS) most 
commonly described in SCD [5,19,20]. Ongoing hemolysis, vaso-occlusive injury, 
endothelial dysfunction, proteinuria, and to a lesser degree, iron deposition likely contribute 
to continuing renal injury.
The pathophysiology of kidney disease in SCT is thought to have similar, but attenuated, 
processes as those for SCD although there are limited data to support this. 
Microangiographic studies of the kidney in SCT individuals demonstrate vascular disruption 
compared to normal controls, but less severe than patients with SCD [1]. While patients with 
SCT do exhibit hematuria, impaired urinary concentration, and albuminuria, and the other 
features of CKD common to SCD have not been examined in detail in SCT [5,21].
3. Epidemiology
3.1. Hematuria and renal papillary necrosis
Perhaps, the most common renal abnormality noted in individuals with SCD and SCT is that 
of hematuria [21]. The etiology of hematuria is presumed to be due to vaso-occlusive events, 
microinfarction, and subsequent ischemic parenchymal injury and may present as 
microscopic or painless gross hematuria. The left kidney is more commonly involved, 
presumptively due to its slightly larger size and higher venous pressure resulting from 
compression of the left renal vein by the aorta and superior mesenteric vein [21]. The most 
profound manifestation of these ischemic events is renal papillary necrosis, with infarction 
of the renal papillae leading to gross hematuria and potentially even ureteral obstruction due 
to clot and/or tissue sloughing. Potential additional contributors to papillary necrosis include 
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analgesic use, concomitant cirrhosis, diabetes mellitus, pyelonephritis, systemic vasculitis, 
renal vein thrombosis, or urinary tract obstruction [22].
3.2. Impaired urinary concentration
One of the earliest manifestations of renal disease in sickling hemoglobinopathies is 
impaired concentrating ability (hyposthenuria) [23]. Early studies demonstrated a dose-
dependent relationship between concentration of HbS and degree of hyposthenuria, with 
individuals with hemoglobin SS or Sβ° genotypes (sickle cell anemia, SCA) demonstrating 
severely impaired concentrating ability (inability to concentrate urine to >450 mOsm/kg 
with water deprivation) starting in infancy and those with SCT demonstrating a later onset of 
impairment usually by age 10 [24]. This impaired ability to concentrate urine starting at a 
young age is thought to relate to the increased prevalence of nocturnal enuresis among 
children and adolescents with SCD [25], a phenomenon that may persist into adulthood [26].
3.3. Hyperfiltration
In addition to hyposthenuria, hyperfiltration—variably defined as GFR ≥ 90–140 mL/min/
1.73 m2 [27]—is also frequently observed in children with SCD, often as early as infancy. In 
the BABY HUG study, elevated glomerular filtration rate (GFR) ≥ 110 mL/min/1.73 m2 as 
measured directly by plasma clearance of 99mTc-DTPA was present in over 50% of infants 
from 9 months to 1 year and demonstrated progressive escalation with increasing age 
beyond 15–19 months [28]. This increase in GFR appears to continue to progress well into 
young adulthood with nearly all children >2.5 years of age demonstrating elevated GFR in 
the HUSTLE study [29], and nearly all adults age 18–30 years also demonstrating high 
creatinine-based eGFR ≥ 130 mL/min/1.73 m2 [30]. As the degree of renal clearance 
declines, however, eGFR levels also appear to drop off, starting around age 30–40 [30]. 
Whether similar glomerular hyperfiltration occurs in SCT is unknown, although one small 
study of Congolese children suggested that hyperfiltration defined as creatinine-based eGFR 
>140 mL/min/1.73 m2 was more common in SCT than hemoglobin AA controls [31].
As a correlate to glomerular hyperfiltration, increased GFR in SCD results in proximal 
tubular hyper-functioning and creatinine hypersecretion. Creatinine levels in individuals 
with SCD have been noted to be lower than controls, suggesting that estimates of creatinine 
clearance may underestimate renal dysfunction in SCD. In fact, creatinine-based estimation 
equations for GFR all appear to overestimate kidney function when compared to 
radionucleotide measures of GFR [32]. Because of this phenomenon, cystatin C has been 
suggested as a more accurate marker of CKD in both children and adults with SCD with 
GFR greater than 30 mL/min/1.73 m2 [27,33]. In SCT, cystatin C-based eGFR was 
associated with higher prevalence of low eGFR <60 mL/min/1.73 m2 compared to 
creatinine-based estimations, but correlations with direct measures of GFR have not been 
investigated [34].
3.4. Albuminuria
Similar to diabetic nephropathy, hyperfiltration appears to result in progressive glomerular 
injury in SCD. Baseline hyperfiltration of eGFR >130–140 mL/min/1.73 m2 is associated 
with the development of microalbuminuria (urine albumin 30–299 mg/g creatinine) in adults 
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with SCA [30]. Albuminuria >30mg/g has also been found in over 20% of SCD children, 
with greater than 60% of patients with SCA demonstrating albuminuria by adulthood 
[35,36]. Progression to macroalbuminuria >300 mg/g affects nearly 40% of adults with SCA 
by age 40 [36]. Nephrotic range proteinuria, however, is rare and only occurred in only 
12/250 (4%) of SCD patients in one series, with the pathology attributed to progressive 
sickle glomerulopathy rather than an alternative cause in a majority of cases [37].
In SCT, a study of four population-based United States cohorts found that 31.7% of African 
American adults with SCT had baseline albuminuria >30 mg/g, with an odds ratio (OR) if 
1.86 (1.49–2.31) comparing those with and without SCT [34]. These findings have been 
further extended to SCT individuals of Hispanic/Latino ancestry [38]. Similar studies in 
children with SCT have not been performed; therefore, the age at onset of these changes in 
SCT is unknown.
3.5. Chronic kidney disease
Progression of glomerular damage ultimately leads to eGFR decline in SCD and SCT 
patients, even as measured by creatinine-based estimates. In one adult SCD cohort with 
mean age 31.6 years, nearly 30% had baseline CKD defined as eGFR <60 mL/min/1.73 m2 
and/or albuminuria >150 mg/g, which progressed to a prevalence of 41.8% over 5 years 
[39]. In SCT, 36.8% of African Americans were found to have CKD by eGFR and 
albuminuria criteria by a mean age of about 60 years, compared to 25% prevalence in non-
SCT adults [40], resulting in about a 1.5–2 fold risk of CKD in SCT carriers of African or 
Hispanic ancestry compared to noncarriers [34,38]. Studies using directly measured GFR in 
SCD and SCT patients with late-stage kidney disease, however, have not been performed.
3.6. End-stage renal disease
Advanced CKD and ESRD, though infrequent complications, are associated with significant 
morbidity and mortality in SCD. In a large cohort of >1000 SCA patients, renal failure was 
noted in 12% of patients with a median age of onset of 37 years. That study also noted that 
14% of SCD deaths were directly attributable to renal disease, second only to chronic lung 
disease and pulmonary hypertension [41]. Advanced CKD was also demonstrated to be the 
most common etiology of death in the Cooperative Study of Sickle Cell Disease (CSSCD) 
among patients with chronic organ failure, comprising 10.5% of total deaths [42]. In SCD 
patients over the age 60, advanced CKD is a major cause or contributor to death in 43% of 
patients [43].
Studies investigating the relationship between SCT and ESRD, however, have been 
conflicting. A cross-sectional analysis of ESRD patients on dialysis demonstrated an 
increased prevalence of SCT among those with ESRD compared to expected population 
prevalence [44], but a subsequent case-control of diabetic, hypertension-attributed, and 
glomerular disease-associated ESRD did not find an association with SCT [45]. More 
recently, longitudinal data from a large, population-based cohort do suggest a 2-fold 
increased risk of developing ESRD in SCT compared to noncarrier controls [40]. The 
influence of this potential increase in ESRD risk among SCT carriers on mortality has not 
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been determined, though prior studies have demonstrated no increase in overall mortality 
among individuals with SCT [46].
4. Modifying factors
4.1. Age
Age is by far the most potent modifying factor of sickle nephropathy, as described in the 
prior section. Progression to overt CKD appears to occur by early adulthood (age 20–30s), 
and as more individuals with SCD are reaching the fourth to sixth decade of life, the 
prevalence and risk of CKD is likely to increase as well. In SCT, the age of onset of renal 
dysfunction is unknown but is expected to be a later age than with SCD.
4.2. Hypertension
The relationship between sickle nephropathy and hypertension has not been well-studied. 
Several studies have found lower mean blood pressures and prevalence of hypertension 
among individuals with SCD compared to controls, even among those with renal disease 
[36,47,48]. It has been hypothesized that this phenomenon may be due to lower urinary 
concentrating ability and urinary sodium loss in individuals with SCD [49]; however, the 
pathophysiology is not clear. Interestingly, in patients with SCA, macroalbuminuria and 
renal insufficiency appear to be associated with resistance to developing hypertension [36] 
Furthermore, a recent multi-center study of SCD has suggested that pulse pressure, rather 
than mean arterial pressure, may be more predictive of SCD-related vasculopathy, including 
in the kidney [50]. Nonetheless, arterial hypertension may be a risk factor for CKD in SCD 
[51]. For example, nocturnal hypertension, based on age-specific criteria, was associated 
with a lower mean eGFR in a pediatric cohort of patients with SCA and relative systemic 
hypertension >120/70 mmHg appears to associate with higher creatinine levels in SCA 
adults [52,53].
The relationship between hypertension and renal disease in SCT is similarly complicated. 
Several United States-based population studies have demonstrated that SCT confers a higher 
risk (2–3 fold) of CKD among African Americans without hypertension compared to an 
only 1.5 increased risk in hypertensive individuals, despite a similar prevalence of 
hypertension in SCT and non-SCT carriers at baseline [34,40]. This may suggest that SCT-
related nephropathy itself results in relative hypotension; however, further studies will be 
needed to elucidate this relationship.
4.3. SCD genotype
As with most complications in SCD, genotype is an important modifier of prevalence and 
severity of CKD. The phenotypic variation observed with sickling genotypes relates to 
differences in degree of hemolysis, endothelial dysfunction, and viscosity, with hemolytic 
complications such as pulmonary hypertension and leg ulcers being more common in SCA 
genotypes and viscosity-related manifestations such as retinopathy and possibly avascular 
necrosis being more common in sickle variant syndromes [54]. Renal medullary 
vasculopathy appears to fit into the former category; albuminuria and advanced renal 
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insufficiency have consistently been found to be more prevalent among individuals with 
SCA compared to those with SC or Sβ+thalassemia [36,55].
4.4. Alpha-thalassemia
The major determinant of rheologic changes (‘sickling’) of erythrocytes in sickling 
hemoglobinopathies is polymerization of sickle hemoglobin. Polymerization is, in turn, 
facilitated by low oxygen saturation and by higher concentration of HbS and is impaired by 
high concentrations of hemoglobin F [56,57]. Alpha-thalassemia deletions, the most 
common of which is the −3.7kb deletion, are found in approximately 30% of African 
Americans and, in the case of SCT, co-inheritance directly relates to decreased HbS 
percentage. Specifically, in SCT, co-inheritance of α-thalassemia gene deletions decreases 
the percentage of HbS in a dose-dependent manner such that individuals with a higher 
number of α-thalassemia deletions demonstrating the lowest percentage of HbS [58]. This 
results in a sickle hemoglobin concentration per erythrocyte range of about 25–45%. This 
phenomenon has been demonstrated to be clinically relevant in the kidney; in one study, α-
thalassemia deletions protected against urinary concentrating defects in individuals with 
SCT in a dose-dependent manner [59]. However, α-thalassemia has not yet been studied in 
other manifestations of renal disease in SCT, such as albuminuria and decreased GFR; 
therefore, the impact on renal disease progression in SCT is unknown.
In SCD, the relationship between α-thalassemia and HbS polymerization is likely more 
complex, but nonetheless, alpha-thalassemia deletions are associated with a decreased risk 
of hemolysis-associated complications such as leg ulcers and stroke [54], a finding that 
appears to translate to CKD. Patients with hemoglobin SS disease who co-inherit at least 1 
copy of an α-thalassemia deletion have a lower prevalence of macroalbuminuria (13%) 
compared to those without α-globin deletions (40%) [60]. Similarly, α-thalassemia was 
significantly associated with the absence of hyperfiltration in a young adult population of 
SCA patients [61]. Another recent study in a cohort of 413 SCD individuals from Cameroon 
also demonstrated a ‘protective’ association between α-thalassemia and macroalbuminuria 
[62].
4.5. Hemoglobin F
As discussed above, hemoglobin F is also a major determinant of HbS polymerization and 
phenotype in SCD. Hemoglobin F percentage in SCD can range from <5% to 20%, with 
several genes being implicated in the variability of levels. Early studies revealed differences 
in % hemoglobin F between sickle haplotypes, with the Senegal and Arab Indian variants 
having the highest hemoglobin F levels (10–20%) and the African Benin and Central 
African Republic (CAR)/Bantu haplotypes having the lowest (~5%) [63]. More recent 
studies have revealed that 20–50% of this hemoglobin F variation is due to polymorphisms 
in the β-globin gene cluster, the HBS1L-MYB intergenic region on chromosome 6, and 
BCL11A on chromosome 2 [64]. Polymorphisms in these genes can lead to nonspecific 
hetero-cellular elevations in hemoglobin F. In SCD, hereditary persistence of fetal 
hemoglobin (HPFH) has been associated with a decreased risk of vaso-occlusive crisis and 
acute chest syndrome [63,65]. Little evidence links increased fetal hemoglobin and renal 
dysfunction; in one longitudinal study of 725 SCD patients, the CAR βs haplotype was 
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associated with a high risk of renal failure [66], and in another study of 144 children with 
SCA, higher hemoglobin F levels were associated with lower prevalence of 
microalbuminuria [67]. A common BCL11A polymorphism was also associated with lower 
albumin/creatinine ratio (ACR) than wild type in an adult cohort of SCD [68]. Studies 
evaluating the effect of hemoglobin F levels on SCT-related nephropathy, however, have not 
yet been performed.
4.6. HMOX1
Interest has recently developed in variants of HMOX1, the gene encoding for the enzyme 
heme oxygenase-1—the enzyme responsible for heme catabolism. A study of 221 SCD 
patients from the University of Illinois at Chicago (UIC) and 487 patients from the Walk-
Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy 
cohort (Walk-PHaSST) demonstrated an association between the HMOX1 rs743811 variant 
with lower eGFR, albuminuria, and CKD stage even after adjusting for APOL1 variants. In 
the Walk-PHaSST cohort, this variant also associated with ESRD. The longer HMOX1 GT-
tandem repeat polymorphism in the UIC cohort was associated with lower eGFR [69]. 
Another smaller study of 152 SCD patients in Europe failed to delineate a relationship 
between the HMOX1 rs743811 variant and kidney disease [70]. However, another study of 
young SCD patients (median age 15 years) from Cameroon demonstrated a trend to 
association between HMOX1 rs743811 and macroalbuminuria, although this did not quite 
reach statistical significance (p = 0.06) [62]. While certainly not definitely associated with 
kidney disease in SCD, these HMOX1 variants do warrant additional examination, 
particularly due to their direct influence on heme catabolism and potential pathophysiologic 
role.
4.7. APOL1
APOL1 high-risk variants (G1/G1, G1/G2, or G2/G2), which are found in about 11–13% of 
African Americans, are the most widely recognized genetic contributors to renal disease. 
Similar to SCT, they have been found to confer a ~ 2-fold higher risk of renal disease 
progression and ESRD among unselected African Americans [40,71]; however, in select 
populations such as hypertension-attributed, FSGS, and HIV associated nephropathy, 
APOL1 variants have been found to confer a significantly greater risk of ESRD, ranging 
from 7- to 29-fold increased risk depending on etiology [72]. Given this strong relationship 
to renal disease, the question of whether co-inheritance of APOL1 high-risk variants 
potentiates the risk of sickle nephropathies has been of considerable interest. Few studies 
have investigated this relationship. In SCD, APOL1 high-risk variants were associated with 
a 3-fold increased risk of proteinuria by dipstick measure but not eGFR in one study of 521 
patients [73]. Another study of 262 adults with SCA demonstrated an association of APOL1 
high-risk variants with albuminuria and renal progression (defined as 50% decline in eGFR 
or ESRD) [68].
In SCT, however, a genetic interaction with APOL1 has not been verified. In two population-
based cohorts with a total of 3,292 African Americans, SCT was associated with a 2.67 (CI 
1.13–6.33) increased risk of albuminuria in individuals with APOL1 high-risk variants 
compared to an OR 1.40 (CI 1.01–1.95) in those without high-risk variants, but this 
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interaction was not statistically significant [34]. Nonetheless, among individuals with SCT, 
50% (12/24) of those with co-inheritance of APOL1 high-risk variants demonstrated 
albuminuria compared to 27% of those without APOL1. A similar trend was not observed 
for CKD defined by eGFR < 60 mL/min/1.73 m2. Another single cohort study of 9909 self-
reported African Americans also demonstrated no significant interaction between APOL1 
and SCT for baseline CKD [40].
4.8. Other genetic modifiers
Additional genetic modifiers have been explored in SCD that may also influence risk of 
CKD. In a cohort of 237 adult SCA patients, lack of Duffy (Fy) antigen expression was 
significantly associated with a 3-fold increase in proteinuria by dipstick measurement, 
possibly due to a loss of inflammatory inhibition [74]. In addition, an exploratory evaluation 
of 1,140 children and adults from the CSSCD found associations between polymorphisms in 
the bone morphogenic protein (BMP) 1B gene and eGFR, also hypothesized to be due to 
impaired inflammatory response [75]. Validation of these studies has yet to be performed. 
Other genetic modifiers of CKD risk in SCD undoubtedly exist and will need to be 
investigated in future studies.
5. Screening guidelines
Evidence-based recommendations for SCD-related complications were developed by a 
National Heart Lung and Blood Institute (NHLBI) expert panel in 2014 [76,77]. Although 
there has been no specific study to guide screening regimens for renal disease in SCD, 
consensus panel recommendations have been based on considerations of cost and potential 
benefits. Most recent guidelines state that all children with SCD should be screened for 
proteinuria annually starting at age 10. If the proteinuria screen is positive by dipstick, a first 
morning urine albumin-to-creatinine or 24 h urinary albumin should be performed and if 
positive, consideration should to taken to consult with or refer to a renal specialist [77]. The 
guidelines additionally state that any patient with macroalbuminuria (>300 mg/24 h) or 
modest elevations in creatinine (>0.7 mg/dL in children, >1.0 mg/dL in adults) should be 
referred to a nephrologist [76].
Formal recommendations for screening for CKD in individuals with SCT are not currently 
available, in part, because evidence of an association of SCT and CKD has only recently 
been documented. However, because screening for sickle hemoglobin is mandated as part of 
newborn screening in all 50 states, the need for additional research to guide screening and 
counseling recommendations in SCT has been increasingly recognized [78].
6. Treatment
The most widely studied treatment for SCD-related nephropathy has been angiotensin-
converting enzyme (ACE)-inhibitors. ACE inhibitors dilate the efferent arterioles leading to 
a decrease in glomerular pressure and albuminuria. Because sickle nephropathy is in part 
due to vasoconstriction and progressive glomerular hypertension, ACE inhibitors have 
offered an attractive therapeutic intervention for SCD-related renal dysfunction [79]. In a 
prospective study of 10 patients with SCD-related proteinuria, enalapril (5–10 mg/day) x 2 
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weeks was found to decrease 24 urinary protein excretion by a mean of 57% [19]. In another 
study of eight patients treated with 6 months of enalapril (5 mg daily) therapy, 7/8 achieved 
normalization of their urinary albumin levels [80]. Given the success of these small studies, 
one of the few randomized controlled trials in SCD was performed to evaluate the efficacy 
of captopril in 22 patients with SCA and microalbuminuria. Captopril (dose escalated from 
6.25 mg daily to 25 mg daily in the first 3 months for a total 6 months) resulted in a 37% 
reduction in urinary albumin compared to +17% increase in the placebo group [81]. Based 
on these results, the NHLBI consensus panel has recommended initiation of an ACE 
inhibitor for all adult SCD patients with albuminuria >30 mg/g.
SCD-specific therapies such as hydroxyurea and chronic transfusion have not been formally 
studied for SCD-related renal complications. In the BABY HUG study, hydroxyurea for 24 
months did not reduce hyperfiltration in 193 infants (mean age 13.8 months) with SCD, but 
did show benefit for hyposthenuria and decreased renal enlargement [82]. An evaluation of 
children in the HUSTLE prospective study, however, did demonstrate an effect of 
hydroxyurea in reducing hyperfiltration among a cohort of 23 older children (median age 7.5 
years) [82]. In a study of 149 adults with SCD, patients on hydroxyurea were only one-third 
as likely to exhibit albuminuria, although this study was limited by its cross-sectional nature 
[83]. A small prospective study of 58 patients noted reduction in albuminuria at 6 months 
after initiation of hydroxyurea, although noted primarily in the microalbuminuria subgroup 
[84]. Due to the paucity of data, there are no specific recommendations regarding 
hydroxyurea use for SCD-related nephropathy, although hydroxyurea has been suggested to 
improve renal disease-associated anemia when used as an adjunct to erythropoiesis-
stimulating agents (ESAs) [77].
In SCT, epidemiologic studies have shown that higher doses of ESAs may be required to 
achieve a hemoglobin response in SCT carriers with ESRD compared to noncarriers [85]. 
However, no formal studies have specifically investigated potential treatments for CKD in 
SCT.
7. Expert commentary
Sickle nephropathy is a common complication of SCD and emerging evidence suggests that 
the spectrum of renal disease extends to SCT. The epidemiology of renal dysfunction in 
SCD has been evaluated in numerous studies and has verified an early onset of albuminuria 
and hyperfiltration in children with a progression to overt CKD by early adulthood. Several 
genetic modifiers of renal disease in SCD have been described and provide an opportunity 
for a precision medicine approach to risk stratify patients who may benefit from early 
intervention. Because CKD is associated with significant morbidity and mortality in SCD, 
the need for effective treatments is essential. ACE inhibitors likely delay progression to 
CKD in SCD patients; however, continued efforts should be made to identify SCD-specific 
therapies—such as hydroxyurea, transfusion therapy, and others—which may have benefit in 
prevention of sickle nephropathy.
Many aspects of the epidemiology of renal disease in SCT have yet to be determined. 
Genetic counseling and screening guidelines for renal dysfunction in SCT require a more in-
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depth knowledge of the scope, age of onset, and rate of progression of renal disease in 
carriers of SCT. Furthermore, insights about the genetic modifiers of nephropathy in SCD 
should be extrapolated to and explored in SCT. For example, α-thalassemia has already been 
shown to be a potent modifier of urinary concentrating ability in SCT, and future research is 
needed to determine if co-inheritance of SCT and α-thalassemia may protect against 
development of overt renal dysfunction. Because many of the existing longitudinal cohorts 
follow a general population with a low prevalence of SCT, a dedicated SCT cohort may be 
necessary to answer these questions. In addition, similar to in SCD, treatments to delay 
progression of nephropathy in SCT carriers are critical, and future studies will need to focus 
on the use of ACE inhibitors and other treatments to delay progression of renal 
complications in SCT.
8. Five-year view
The recent surge in epidemiologic and genetic research in SCD and SCT is likely to lead to 
considerable advances in our understanding of sickle hemoglobin-related nephropathy. In 
particular, we will gain knowledge about the demographic and genetic profile of individuals 
with sickle hemoglobinopathies who are at high risk for progression of their kidney disease. 
A precision medicine approach will allow us to tailor counseling, screening, and treatment 
recommendations for individuals with SCD or SCT and markers of renal dysfunction. We 
will also gain increasing understanding about the pathophysiology of renal disease in 
sickling disorders, which will help guide testing and development of effective therapies.
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Key issues
• Sickle nephropathy is a common complication of sickle cell disease, and early 
markers of renal dysfunction can be found in children with sickle cell disease.
• Overt chronic kidney disease occurs by early adulthood in patients with sickle 
cell disease.
• End-stage renal disease is a rare complication but is associated with high 
mortality in sickle cell disease.
• Genetic modifiers of sickle nephropathy in sickle cell disease include sickle 
cell genotype, α-thalassemia, hemoglobin F, APOL1, and HMOX1.
• Annual screening and treatment with angiotensin-converting enzyme (ACE)-
inhibitors may delay renal disease progression in sickle cell disease.
• The spectrum of sickle hemoglobin-related nephropathy extends to sickle cell 
trait, with sickle cell trait conferring ~2 fold increased risk of chronic kidney 
disease compared to non-carriers.
• Further research is needed to elucidate the epidemiology, genetic modifiers, 
and potential treatment for renal disease in sickle cell trait.
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